Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis
Zomedica (NYSE:ZOM) has announced a significant update to its endogenous ACTH (eACTH) assay for equine plasma on the TRUFORMA biosensor platform. The enhanced test, initially launched in September 2024, now measures both full-length endogenous ACTH and CLIP (Corticotropin-Like Intermediate Peptide), providing a composite value comparable to traditional laboratory results.
The advancement represents a potential breakthrough in diagnosing Pituitary Pars Intermedia Dysfunction (PPID), a common equine endocrine disorder. The updated assay is particularly notable as it's the first to enable simultaneous measurement of both CLIP and full-length ACTH in a clinical setting, offering veterinarians a more comprehensive diagnostic tool at the point-of-care.
Zomedica (NYSE:ZOM) ha annunciato un aggiornamento significativo al suo saggio di ACTH endogeno (eACTH) per il plasma equino sulla piattaforma biosensor TRUFORMA. Il test migliorato, lanciato inizialmente a settembre 2024, ora misura sia l'ACTH endogeno a lunghezza completa che il CLIP (Corticotropina-Like Intermediate Peptide), fornendo un valore composito comparabile ai risultati dei laboratori tradizionali.
Questo progresso rappresenta una potenziale innovazione nella diagnosi della Disfunzione della Pars Intermedia dell'ipofisi (PPID), un comune disturbo endocrino equino. Il saggio aggiornato è particolarmente significativo in quanto è il primo a consentire la misurazione simultanea sia del CLIP che dell'ACTH a lunghezza completa in un contesto clinico, offrendo ai veterinari uno strumento diagnostico più completo al punto di cura.
Zomedica (NYSE:ZOM) ha anunciado una actualización significativa a su ensayo de ACTH endógeno (eACTH) para plasma equino en la plataforma biosensor TRUFORMA. La prueba mejorada, lanzada inicialmente en septiembre de 2024, ahora mide tanto ACTH endógeno de longitud completa como CLIP (Péptido Intermedio Similar a la Corticotropina), proporcionando un valor compuesto comparable a los resultados de laboratorio tradicionales.
Este avance representa un posible avance en el diagnóstico de la Disfunción de la Pars Intermedia de la hipófisis (PPID), un trastorno endocrino equino común. El ensayo actualizado es particularmente notable ya que es el primero en permitir la medición simultánea tanto de CLIP como de ACTH de longitud completa en un entorno clínico, ofreciendo a los veterinarios una herramienta diagnóstica más completa en el punto de atención.
조메디카 (NYSE:ZOM)는 TRUFORMA 바이오센서 플랫폼을 위한 내인성 ACTH(eACTH) 분석법에 대한 중요한 업데이트를 발표했습니다. 2024년 9월에 처음 출시된 이 향상된 테스트는 이제 전체 길이 내인성 ACTH와 CLIP(코르티코트로핀 유사 중간 펩타이드)를 측정하여 전통적인 실험실 결과와 비교 가능한 복합 값을 제공합니다.
이 발전은 말의 일반적인 내분비 장애인 뇌하수체 중간엽 기능 장애(PPID) 진단에 있어 잠재적인 돌파구를 의미합니다. 업데이트된 분석법은 임상 환경에서 CLIP와 전체 길이 ACTH를 동시에 측정할 수 있는 첫 번째 분석 방법으로, 수의사들에게 현장에서 보다 포괄적인 진단 도구를 제공합니다.
Zomedica (NYSE:ZOM) a annoncé une mise à jour significative de son test ACTH endogène (eACTH) pour le plasma équin sur la plateforme de biosensor TRUFORMA. Le test amélioré, lancé initialement en septembre 2024, mesure désormais à la fois l'ACTH endogène de longueur complète et le CLIP (Péptide Intermédiaire de Type Corticotropine), fournissant une valeur composite comparable aux résultats des laboratoires traditionnels.
Ce progrès représente une avancée potentielle dans le diagnostic de la Dysfonction de la Pars Intermédia de l'hypophyse (PPID), un trouble endocrinien courant chez les chevaux. Le test mis à jour est particulièrement notoire car c'est le premier à permettre la mesure simultanée tant du CLIP que de l'ACTH de longueur complète dans un cadre clinique, offrant aux vétérinaires un outil de diagnostic plus complet sur le lieu de soins.
Zomedica (NYSE:ZOM) hat ein wichtiges Update zu seinem endogenen ACTH (eACTH) Assay für equines Plasma auf der TRUFORMA-Biosensorplattform angekündigt. Der verbesserte Test, der zunächst im September 2024 eingeführt wurde, misst nun sowohl das vollwertige endogene ACTH als auch das CLIP (Corticotropin-ähnliches Zwischenpeptid) und liefert einen zusammengesetzten Wert, der mit den Ergebnissen traditioneller Labore vergleichbar ist.
Der Fortschritt stellt einen potenziellen Durchbruch bei der Diagnose der Funktionsstörung des mittleren Teils der Hypophyse (PPID) dar, einer häufigen endokrinen Störung bei Pferden. Der aktualisierte Assay ist besonders bemerkenswert, da er der erste ist, der in einem klinischen Umfeld eine gleichzeitige Messung von sowohl CLIP als auch vollwertigem ACTH ermöglicht und den Tierärzten ein umfassenderes Diagnosewerkzeug am Point-of-Care bietet.
- First-to-market point-of-care test measuring both CLIP and full-length ACTH simultaneously
- Enhanced diagnostic capabilities compared to previous version
- Direct comparability with traditional laboratory results
- Potential market expansion in equine diagnostics
- Clinical significance of CLIP levels still unknown
- to specific equine condition (PPID) diagnostic market
Insights
The enhanced TRUFORMA eACTH assay marks a pivotal development in Zomedica's diagnostic portfolio, particularly significant as it's the only point-of-care platform capable of measuring both full-length ACTH and CLIP in equine patients. This technological advancement addresses a critical market gap in equine diagnostics, where traditional testing requires sample shipment to reference laboratories, causing delays in diagnosis and treatment.
The platform's ability to provide composite values comparable to reference laboratory results while offering additional CLIP measurements represents a significant competitive advantage. This dual-measurement capability could drive adoption among veterinary practices, particularly those specializing in equine care, as it eliminates the need for multiple tests or external lab services.
The timing of this enhancement, just five months after the initial launch, demonstrates strong R&D execution and responsive product development based on real-world usage data. This rapid iteration cycle suggests robust internal capabilities and potential for continued platform evolution. The validation from respected institutions like the University of Georgia adds credibility and could accelerate market acceptance.
The enhanced assay's potential to advance PPID research and diagnosis positions Zomedica to capture a larger share of the equine diagnostics market, estimated to be growing steadily. By enabling more comprehensive disease understanding and potentially earlier intervention, this advancement could drive increased testing frequency and expand the overall market size for equine diagnostics.
Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform
ANN ARBOR, MI / ACCESS Newswire / February 6, 2025 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic devices for equine and companion animals, today announced a groundbreaking update to its endogenous ACTH (eACTH) assay for equine plasma on the TRUFORMA biosensor platform. Since it was launched in September of 2024, the TRUFORMA eACTH assay has been widely adopted as the only assay to measure eACTH in horses directly at the point-of-care. Leveraging data gathered from its use in the field, Zomedica R&D scientists have now expanded its capabilities and potential utility.
The enhanced test now provides values for both full-length endogenous ACTH and CLIP (Corticotropin-Like Intermediate Peptide) and calculates a composite value that can be directly compared to results from the traditional chemiluminescent assay used at reference laboratories. CLIP is a breakdown product of ACTH and known to have significant cross-reactivity with the assay commonly used in reference laboratories. Recent data indicate that some horses suspected of suffering from Pituitary Pars Intermedia Dysfunction (PPID) have high circulating levels of CLIP, especially in response to TRH stimulation. While the biological function of CLIP and clinical significance of elevated levels of the molecule are currently unknown, the enhanced TRUFORMA Equine eACTH assay provides veterinarians the ability to quantify this molecule for the first time.
This advancement provides a tool that could lead to a significant leap forward in the diagnosis of Pituitary Pars Intermedia Dysfunction (PPID), a common endocrine disorder affecting horses.
"Point-of-care testing with the TRUFORMA platform has already proven to be a valuable tool for equine veterinarians," states Dr. T. J. Barclay, Senior Professional Services Veterinarian for Zomedica. "The enhancements to the eACTH assay will put it on the cutting edge of PPID diagnosis and research."
Research suggests that imbalances in CLIP, full-length ACTH, and related hormones may all play a role in PPID. By enabling the simultaneous and rapid measurement of these biomarkers in a clinical setting, Zomedica's updated assay provides veterinary practitioners and researchers with a more comprehensive tool to assess and understand this complex disease.
"For the first time, veterinarians will have access to a test that concurrently measures both CLIP and full-length ACTH in a clinical setting," said Kelsey Hart, DVM, PhD, DACVIM (LAIM) Professor and Hodgson Chair of Equine Studies at the University of Georgia College of Veterinary Medicine. "This innovation opens new doors for PPID diagnosis and could lead to a deeper understanding of this important equine health condition."
The TRUFORMA platform utilizes state-of-the-art biosensor technology to deliver precise, point-of-care diagnostics, allowing veterinary professionals to make faster, more informed decisions for their equine patients.
For more information on the TRUFORMA eACTH assay and other Zomedica solutions, visit www.zomedica.com/truforma.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices, the TRUFORMA diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
What new features does Zomedica's enhanced TRUFORMA eACTH assay offer?
When was the original TRUFORMA eACTH assay launched by ZOM?
How does ZOM's enhanced TRUFORMA eACTH assay benefit veterinarians?
What condition does ZOM's enhanced TRUFORMA eACTH assay help diagnose?
What makes ZOM's TRUFORMA eACTH assay unique in the market?
